Evidence map›Paper›PMID 41476213›Full record

ArticleBMC biotechnology2025

Purification and immunogenicity of Nipah virus-like particles from insect cells.

Urban Bezeljak, Alexander Jerman, Tina Kobal, Martina Lokar Kosmač, Elfi Birsa, Marko Kolenc, Dániel Déri, Bernadett Pályi, Zoltán Kis, Matjaž Peterka

Abstract read
In one paragraph

Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Urban BezeljakSferogen d.o.o., Ajdovščina, Slovenia. urban.bezeljak@sferogen.com.ORCID 0000-0003-1365-5631
Alexander JermanSferogen d.o.o., Ajdovščina, Slovenia.ORCID 0000-0001-9891-7500
Tina KobalCOBIK, Ajdovščina, Slovenia.ORCID 0009-0005-6591-5003
Martina Lokar KosmačCOBIK, Ajdovščina, Slovenia.ORCID 0009-0009-8931-1756
Elfi BirsaCOBIK, Ajdovščina, Slovenia.ORCID 0000-0002-7661-2850
Marko KolencInstitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-1003-9131
Dániel DériNational Biosafety Laboratory, National Center for Public Health and Pharmacy, Budapest, Hungary.ORCID 0000-0002-9078-4923
Bernadett PályiNational Biosafety Laboratory, National Center for Public Health and Pharmacy, Budapest, Hungary.ORCID 0000-0003-1975-4198
Zoltán KisNational Biosafety Laboratory, National Center for Public Health and Pharmacy, Budapest, Hungary.
Matjaž PeterkaCOBIK, Ajdovščina, Slovenia.

Funding

HORIZON EUROPE Research Infrastructures 101046133Slovenian Research and Innovation Agency P3-0083
6 · The paper itself

Abstract

Nipah virus (NiV) is an emerging high-fatality zoonotic threat lacking approved vaccines. Current virus-like particle (VLP) production methods rely on costly mammalian cell systems and non-scalable ultracentrifugation purification. We developed an alternative enveloped Nipah virus-like particle (NiVLP) expression system in Sf9 insect cells by co-expressing structural proteins F, G, and M using a single recombinant baculovirus. A novel multi-step chromatographic purification process was established using monolith convective media, integrating steric exclusion chromatography with sequential cation and anion exchange steps. Purified NiVLPs were characterized by nanoparticle tracking analysis and transmission electron microscopy, followed by immunogenicity study in Syrian golden hamsters. The optimized process yielded enveloped particles of approximately 100–120 nm that morphologically resemble native NiV virions. A single 25 µg NiVLP dose induced robust systemic anti-NiV G IgG responses within 14 days, demonstrating rapid immunogenicity suitable for outbreak response. However, neutralizing antibody titers against NiV remained limited compared to total IgG responses. This study establishes the first chromatography-based manufacturing platform for morphologically correct NiVLPs from insect cells. A deeper understanding of the immunity generated is needed to support their potential as a rapidly deployable vaccine platform against NiV.

Indexed as

Nipah VirusVaccines, Virus-Like ParticleAnimalsAntibodies, NeutralizingAntibodies, ViralBaculoviridaeCricetinaeMesocricetusSf9 CellsSpodopteraAntibodies, NeutralizingAntibodies, ViralVaccines, Virus-Like ParticleBaculovirus expressionInsect cell cultureMonolith chromatographyNipah virusPandemic preparednessVaccine developmentVirus-like particles

Identifiers

PMID41476213
PMCPMC12866483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.